The purpose of this clinical study is to evaluate safety and immunogenicity in adult healthy volunteers of the vaccine candidate against schistosomiasis named Bilhvax.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Timeframe: D1 : administration, clinical observation, clinical analysis
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Timeframe: D21 : clinical observation, clinical analysis
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Timeframe: D28 : administration, clinical observation, clinical analysis
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Timeframe: D29 : clinical observation, clinical analysis
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Timeframe: D120 : clinical observation, clinical analysis
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Timeframe: D150 : administration, clinical observation, clinical analysis
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Timeframe: D165 : clinical observation, clinical analysis
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Timeframe: D180 : clinical observation, clinical analysis